Obesity Is an Independent Predictor of Poor Survival in Metastatic Breast Cancer: Retrospective Analysis of a Patient Cohort Whose Treatment Included High-Dose Chemotherapy and Autologous Stem Cell Support
Figure 2
Overall survival (OS) from diagnosis (a) and from time of metastasis (b) and progression-free survival (PFS) from diagnosis (c) and from time to metastasis (d) in patients with a BMI ≤ 30 () or >30 (). Survival was estimated using Kaplan-Meier method.